|
1
|
El-Serag HB and Mason AC: Rising incidence
of hepatocellular carcinoma in the United States. N Engl J Med.
340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM,
Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al: use of arsenic
trioxide (As2O3) in the treatment of acute
promyelocytic leukemia (APL). II Clinical efficacy and
pharmacokinetics in relapsed patients. Blood. 89:3354–3360.
1997.PubMed/NCBI
|
|
3
|
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS,
Wu W, Zhang FQ, Chen Y, Zhou L, et al: Studies on treatment of
acute promyelocytic leukemia with arsenic trioxide: Remission
induction, follow-up, and molecular monitoring in 11 newly
diagnosed and 47 relapsed acute promyelocytic leukemia patients.
Blood. 94:3315–3324. 1999.PubMed/NCBI
|
|
4
|
Munshi NC, Tricot G, Desikan R, Badros A,
Zangari M, Toor A, Morris C, Anaissie E and Barlogie B: Clinical
activity of arsenic trioxide for the treatment of multiple myeloma.
Leukemia. 16:1835–1837. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin YC, Li DR and Lin W: Relationship
between radiotherapy enhancing effect of arsenic trioxide and the
proliferation and apoptosis of related protein in nasopharyngeal
carcinoma patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 27:704–707.
2007.In Chinese. PubMed/NCBI
|
|
6
|
Welch JS, Klco JM, Gao F, Procknow E, Uy
GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF,
Hassan A, et al: Combination decitabine, arsenic trioxide, and
ascorbic acid for the treatment of myelodysplastic syndrome and
acute myeloid leukemia: A phase I study. Am J Hematol. 86:796–800.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beer TM, Tangen CM, Nichols CR, Margolin
KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D and Crawford ED:
Southwest Oncology Group phase II study of arsenic trioxide in
patients with refractory germ cell malignancies. Cancer.
106:2624–2629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang HS, Bae SM, Kim YW, Kwak SY, Min HJ,
Bae IJ, Lee YJ, Shin JC, Kim CK and Ahn WS: Comparison of diarsenic
oxide and tetraarsenic oxide on anticancer effects: Relation to the
apoptosis molecular pathway. Int J Oncol. 30:1129–1135.
2007.PubMed/NCBI
|
|
9
|
Han MH, Lee WS, Lu JN, Yun JW, Kim G, Jung
JM, Kim GY, Lee SJ, Kim WJ and Choi YH: Tetraarsenic hexoxide
induces Beclin-1-induced autophagic cell death as well as
caspase-dependent apoptosis in u937 human leukemic cells. Evid
Based Complement Alternat Med. 2012:2014142012. View Article : Google Scholar
|
|
10
|
Guttridge DC, Albanese C, Reuther JY,
Pestell RG and Baldwin AS Jr: NF-kappaB controls cell growth and
differentiation through transcriptional regulation of cyclin D1.
Mol Cell Biol. 19:5785–5799. 1999.PubMed/NCBI
|
|
11
|
Lee HY, Moon H, Chun KH, Chang YS, Hassan
K, Ji L, Lotan R, Khuri FR and Hong WK: Effects of insulin-like
growth factor binding protein-3 and farnesyltransferase inhibitor
SCH66336 on Akt expression and apoptosis in non-small-cell lung
cancer cells. J Natl Cancer Inst. 96:1536–1548. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jang JS, Lee WS, Lee JS, Kim HW, Ko GH and
Ha WS: The expression of thymidine phosphorylase in
cancer-infiltrating inflammatory cells in stomach cancer. J Korean
Med Sci. 22(Suppl 22): S109–S114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aggarwal BB: Nuclear factor-kappaB: The
enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Motokura T and Arnold A: PRAD1/cyclin D1
proto-oncogene: Genomic organization, 5′ DNA sequence, and sequence
of a tumor-specific rearrangement breakpoint. Genes Chromosomes
Cancer. 7:89–95. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gilmore TD: Introduction to NF-kappaB:
Players, pathways, perspectives. Oncogene. 25:6680–6684. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim DS, Park SS, Nam BH, Kim IH and Kim
SY: Reversal of drug resistance in breast cancer cells by
transglutaminase 2 inhibition and nuclear factor-kappaB
inactivation. Cancer Res. 66:10936–10943. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kerbauy DM, Lesnikov V, Abbasi N, Seal S,
Scott B and Deeg HJ: NF-kappaB and FLIP in arsenic trioxide
(ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood.
106:3917–3925. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davies B, Waxman J, Wasan H, Abel P,
Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F:
Levels of matrix metalloproteases in bladder cancer correlate with
tumor grade and invasion. Cancer Res. 53:5365–5369. 1993.PubMed/NCBI
|
|
19
|
Bogenrieder T and Herlyn M: Axis of evil:
Molecular mechanisms of cancer metastasis. Oncogene. 22:6524–6536.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vihinen P and Kähäri VM: Matrix
metalloproteinases in cancer: Prognostic markers and therapeutic
targets. Int J Cancer. 99:157–166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nishida N, Yano H, Nishida T, Kamura T and
Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag.
2:213–219. 2006. View Article : Google Scholar
|
|
22
|
Correia M, Cravo M, Marques-Vidal P,
Grimble R, Dias-Pereira A, Faias S and Nobre-Leitão C: Serum
concentrations of TNF-alpha as a surrogate marker for malnutrition
and worse quality of life in patients with gastric cancer. Clin
Nutr. 26:728–735. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen ZJ, Parent L and Maniatis T:
Site-specific phosphorylation of IkappaBalpha by a novel
ubiquitination-dependent protein kinase activity. Cell. 84:853–862.
1996. View Article : Google Scholar : PubMed/NCBI
|
